BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Activating potassium channel KCNJ3 to treat epilepsy

DISEASE CATEGORY: Neurology INDICATION: Epilepsy A thiophenylurea-based activator of the potassium channel KCNJ3 could treat epilepsy. In a mouse model of chemically induced epilepsy, the KCNJ3 activator reduced seizure severity and the duration of tonic...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...to three partial responses and 11 cases of stable disease. Innate has also focused on KIRs...
BioCentury | May 9, 2018
Translation in Brief

The fate of NK cells

...indicators, including the killer cell lectin-like receptor subfamily C member 1 (NKG2A; CD159a; KLRC1) and killer cell immunoglobulin-like receptors (KIRs)...
...weakest response to the lymphoma and leukemia cells. But NK cells expressing KLRC2, CD57 and KIRs...
...and -negative cancer cell lines with NK cells expressing combinations of self- and non-self-specific inhibitory KIRs...
BioCentury | Mar 9, 2018
Company News

BMS, Innate say no plans to table lirilumab just yet

...for the products (see BioCentury, July 28, 2014 ). Lirilumab is a human mAb against killer cell immunoglobulin-like receptors (KIRs)...
...#), ipilimumab (Generic), Yervoy (Other) Bristol-Myers Squibb Co. Innate Pharma S.A. Ono Pharmaceutical Co. Ltd. Cytotoxic T-lymphocyte associated protein 4 Killer cell immunoglobulin-like receptors Programmed...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Neurology

INDICATION: Depression Rat studies suggest inhibiting KCNJ10 in the lateral habenula could help treat depression. In a rat model of depression, astrocyte levels of KCNJ10 in the lateral habenula were higher than in normal rats....
BioCentury | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

A Zhejiang University team published a pair of papers in Nature suggesting ketamine works by modulating the firing of neurons in the lateral habenula, a brain region that controls reward signaling. The studies point to...
BioCentury | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

...BioCentury, July 28, 2014 & Jan. 12, 2017 ). Lirilumab is a human mAb against killer cell immunoglobulin-like receptors (KIRs)...
...cell immunoglobulin-like receptor two domains long cytoplasmic tail 1 (KIR2DL1); KIR2DL2 Description: Human mAb against killer cell immunoglobulin-like receptors (KIRs)...
Items per page:
1 - 10 of 82